Dr. Joseph Bertino Pharm.D.

Independent Consultant, Bertino Consulting

Member of the Healthcare Council

Request a consultation with Joseph Bertino

Council Member Biography

Joseph Bertino, PharmD, is an Associate Professor of Pharmacology at Columbia University College of Physicians and Surgeons in New York. Through Bertino Consulting, he consults to the pharmaceutical industry in areas of infectious diseases, drug metabolism, and clinical pharmacology. Dr. Bertino's research interests are in vaccines, antimicrobial pharmacokinetics and pharmacodynamics, pharmacogenetics, and pharmacogenomics. His publications include work in the area of aminoglycoside pharmacokinetics, pharmacodynamics and toxicity, drug-drug interactions, vaccine pharmacology, and application of pharmacogenetics to the drug development process. Dr. Bertino has also served on the Food and Drug Administration's Anti-infective and Antiviral Advisory Committees and remains as a special government employee. He is a recipient of the American College of Clinical Pharmacology Distinguished Investigator Award and the American College of Clinical Pharmacy Clinical Practice award. (This is me - Update Profile)

Employment History

2007 - Unspecified: Independent Consultant, Bertino Consulting
2005 - 2007: Scientific Director in Drug Development Center, ORDWAY RESEARCH INSTITUTE INC
2005 - Unspecified: Associate Professor of Pharmacology, COLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS
1997 - 2005: Associate Professor of Clinical Pharmacology, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
1982 - 2005: Section Chief of Clinical Pharmacology, BASSETT, MARY IMOGENE HOSPITAL INC

GLG News^SM Analyses by Joseph Bertino

Opinions and analyses expressed in G+ Insights are solely those of the author. See the Terms of Use for details.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Gene Targeted Drug Therapy for Heart Failure

September 23, 2008

Analysis of:Gene Targeted Drug Therapy for Heart Failure | www.bio-medicine.org

-Another step towards invididualized medicine -Proves that old drugs can be reinvented for useful purposes -Advances pharmacogenetics forward

Astra-Zeneca and Abbott partner on promoting Crestor..should Pfizer beware?

August 15, 2008

Analysis of:Abbott signs deal to promote Crestor in U.S. | www.chicagotribune.com

-Crestor sold 2.8 billion dollars in sales in the recent year, will this partnership result in long term exponential growth? -What are the implications for Crestor with generic simvastatin and with Lipitor going generic in the next few years? -Is a combination product going to bolster Crestor sales?

The New PhRMA “Code on Interactions with Health Care Professionals”: What will it mean?

July 17, 2008

Analysis of:PhRMA “Code on Interactions with Health Care Professionals” | www.thepinksheet.com

-The new code will limit all gifts and meals to healthcare professionals, thus reducing pharmaceutical representative contact time. -Medical education programs will follow guidelines established by professional education groups -The guidelines do not go far enough for sales representative-healthcare professional interactions

Non-Inferiority Studies: What do the numbers mean, how does the FDA interpret them?

October 11, 2007

Analysis of:Efficacy of Iclaprim in Complicated Skin and Skin Structure Infections: Preliminary Results of ASSIST-1 | www.idsociety.org

A recent abstract for the 2007 Infectious Diseases Society of American (IDSA) meeting has generated some concern among financial analysts. This non-inferiority study on iclaprim versus linezolid for treatment of complicated skin and skin structure infections showed that “The 95% CI for treatment difference (ICL-LZD) in the PP population was -8.4, -1.0%.” Because the 95% CI did not reach or cross 0, many individuals fear that the FDA will hold up approval of this compound. 2007 Infectious Diseases Society of American (IDSA) Abstract: http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={1E0D62C0-A5C5-49E5-883B-C0A0DC4D4745}&SKey={713BCC51-9119-49CC-BE88-A6043DC73587}&MKey={2BC0388C-EE56-4FA2-A529-EC82E2C7362A}&AKey={456A1804-CC97-4677-BF53-D872148C9EF7}

Will all adults over 60 get this vaccine?

August 2, 2006

Analysis of:FDA approves Zostavax, Merck's new vaccine for preventing shingles in adults 60 and older | www.therapeuticsdaily.com

-First vaccine to prevent or reduce herpes zoster infection
-Zoster has some health implications
-Zoster has some important cost implications.

Request a consultation with Joseph Bertino